#8 - Johnson & Johnson (NYSE:JNJ)
To get excited about Johnson & Johnson (NYSE:JNJ) stock you have to look away from the short term news. Over the last two years, two major lawsuits have made the company’s stock more volatile than usual. However, the company has been resilient. First, the company recently posted a solid earnings report that calmed investors. And second, the company is one of several companies on the forefront of the ongoing race to develop a vaccine for the Covid-19 virus (aka: coronavirus).
Over the last five years, the company’s stock is up over 35%. And remember, this is a presentation about stocks you can buy and hold for a long time, so you’re looking for proven performance over time. You’re also looking for value. Brand Finance ranked Johnson & Johnson as the most valuable pharma company for 2020. The company is currently worth $10.9 billion.
And if the company provides a nice dividend as a bonus, that’s even better. Johnson & Johnson is a Dividend King, which means they have a 50 year history of increasing its dividend. Prior to 2020, the company had increased its dividend for 57 years and counting.
About Johnson & Johnson
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.
More about Johnson & Johnson- Current Price
- $167.72
- Consensus Rating
- Moderate Buy
- Ratings Breakdown
- 9 Buy Ratings, 9 Hold Ratings, 0 Sell Ratings.
- Consensus Price Target
- $171.33 (2.2% Upside)
